52 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
therapeutic benefit of this class of new agents permits us to identify targets and disease that we wish to exploit and then, through formulation design … protection and confidentiality agreements and other contractual arrangements with its employees, clients, strategic partners, acquisition targets
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
specific metabolic targets. In addition, other companies including Pfizer, Teijin, Takeda, Merck, are developing new treatments for cardiovascular … of this class of new agents permits us to identify targets and disease that we wish to exploit and then through formulation design optimize those small
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
) the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
activity. The capability of tailoring the potential therapeutic benefit of this class of new agents permits us to identify targets and disease … partners, acquisition targets and others to protect proprietary rights. There can be no assurance that the steps taken by the Company to protect proprietary
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
therapeutic benefit of this class of new agents permits us to identify targets and disease that we wish to exploit and then, through formulation design … protection and confidentiality agreements and other contractual arrangements with its employees, clients, strategic partners, acquisition targets
424B3
ctt84jfmye0fx
13 Jun 24
Prospectus supplement
4:11pm
424B3
sbiu46u4kxoh
13 Jun 24
Prospectus supplement
4:10pm
424B3
8vaxah0xn687z797r3r
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
jgx7e3bvq7o zduej78u
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
gy4xzoqifel0o9c 912
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
424B5
2e0 wixo40kdnyw1
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
8cun jyxzrxfwui7n8
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
u7k3yp1rj
25 Aug 23
Prospectus supplement
6:00am
424B3
54q636 uh6d3xlp47
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
ggxpbj ls
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
vqx fjkwv
14 Aug 23
Prospectus supplement
4:42pm
424B3
lwctba05nhm udqkm
14 Aug 23
Prospectus supplement
4:40pm
POS AM
ly89rcrvy5pl20dnifn
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm